<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03725007</url>
  </required_header>
  <id_info>
    <org_study_id>M15-340</org_study_id>
    <secondary_id>2018-000715-25</secondary_id>
    <nct_id>NCT03725007</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic Arthritis</brief_title>
  <official_title>An Open-Label Multiple-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to evaluate pharmacokinetics, safety and tolerability of upadacitinib in
      pediatric participants with polyarticular course juvenile idiopathic arthritis. This study
      consists of two parts: Part 1 is multiple-cohort study that consists of two sequential
      multiple-ascending dose groups. Participants benefiting from the study drug with no ongoing
      adverse events of special interest or serious adverse events will have option to enroll in
      Part 2. Part 2 is open-label, long term extension study to evaluate safety and tolerability.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 24, 2019</start_date>
  <completion_date type="Anticipated">August 10, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Up to Day 7</time_frame>
    <description>Adverse Event is defined as any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax)</measure>
    <time_frame>Day 7</time_frame>
    <description>Cmax is defined as the maximum observed plasma concentration for upadacitinib.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to maximum observed plasma concentration (Tmax)</measure>
    <time_frame>Day 7</time_frame>
    <description>Tmax is defined as the time to maximum plasma concentration (Cmax) of upadacitinib.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under plasma concentration versus time curve during a dosing interval (AUCtau)</measure>
    <time_frame>Day 7</time_frame>
    <description>The area under the plasma concentration-time curve is a method of measurement of the total exposure of a drug in plasma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent oral clearance at steady state (CL/F)</measure>
    <time_frame>Day 7</time_frame>
    <description>Clearance is defined as the volume of plasma cleared of the drug per unit time.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Half-life</measure>
    <time_frame>Day 7</time_frame>
    <description>Half life of updadacitinib will be determined using non-compartmental method.</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Juvenile Idiopathic Arthritis (JIA)</condition>
  <arm_group>
    <arm_group_label>Participants of age group 12 to &lt;18 years receiving dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants of age group 12 to &lt;18 years administered with upadacitinib dose A(weight dependent) as described in the protocol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Participants of age group 12 to &lt;18 years receiving dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants of age group 12 to &lt;18 years administered with upadacitinib dose B(weight dependent) as described in the protocol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Participants of age group 6 to &lt;12 years receiving dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants of age group 6 to &lt;12 years administered with upadacitinib dose A(weight dependent) as described in the protocol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Participants of age group 6 to &lt;12 years receiving dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants of age group 6 to &lt;12 years administered with upadacitinib dose B(weight dependent) as described in the protocol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Participants of age group 2 to &lt;6 years receiving dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants of age group 2 to &lt;6 years administered with upadacitinib dose A(weight dependent) as described in the protocol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Participants of age group 2 to &lt;6 years receiving dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants of age group 2 to &lt;6 years administered with upadacitinib dose B(weight dependent) as described in the protocol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Upadacitinib</intervention_name>
    <description>Upadacitinib is administered as an oral solution or tablet as described in protocol.</description>
    <arm_group_label>Participants of age group 12 to &lt;18 years receiving dose A</arm_group_label>
    <arm_group_label>Participants of age group 12 to &lt;18 years receiving dose B</arm_group_label>
    <arm_group_label>Participants of age group 2 to &lt;6 years receiving dose A</arm_group_label>
    <arm_group_label>Participants of age group 2 to &lt;6 years receiving dose B</arm_group_label>
    <arm_group_label>Participants of age group 6 to &lt;12 years receiving dose A</arm_group_label>
    <arm_group_label>Participants of age group 6 to &lt;12 years receiving dose B</arm_group_label>
    <other_name>ABT-494</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant have total body weight of 10 kg or higher at the time of screening.

          -  Participant diagnosed with pcJIA (rheumatoid factor-positive or rheumatoid
             factor-negative polyarticular JIA, extended oligoarticular JIA, or systemic JIA with
             active arthritis and without active systemic features) with a history of arthritis
             affecting at least 5 joints during the first 6 months of disease (for extended
             oligoarticular JIA: &lt;=4 joints during first 6 months of disease and &gt;4 joints
             thereafter).

          -  Participant have 5 or more active joints at the time of screening, defined as the
             presence of swollen joints (not due to deformity) or, in the absence of swelling,
             joints with the limitation of movement (LOM) plus pain on motion and/or tenderness
             with palpitation, with LOM present in at least three of the active joints.

          -  If receiving methotrexate (MTX), have been taking MTX for at least 12 weeks
             immediately before and including Study Day 1 on an stable dose of 10 to 20 mg/m2 for
             at least 8 weeks before and including Study Day 1; in addition, participants should
             take either folic acid or folinic acid according to local standard of care.

          -  If on oral glucocorticosteroids, must have been taking oral glucocorticosteroids at a
             stable dose (no greater than 10 mg/day or 0.2 mg/kg/day, whatever is lower) for at
             least 1 week before and including Study Day 1.

        Exclusion Criteria:

          -  Participant with diagnosis of enthesitis-related arthritis (ERA) or juvenile psoriatic
             arthritis (JPSA).

          -  Participant have prior exposure to JAK inhibitor.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>847.283.8955</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital of Chicago /ID# 211162</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Louisville /ID# 202896</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Boston Childrens Hospital /ID# 202993</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cincinnati Childrens Hosp Med /ID# 209697</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Randall Children's Hospital /ID# 213609</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97227-1654</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia /ID# 209617</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19146-2305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC /ID# 202994</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224-1334</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital /ID# 203003</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>PRI - Pediatric Rheumatology Research Institute /ID# 205954</name>
      <address>
        <city>Bad Bramstedt</city>
        <zip>24576</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Helios Klinikum Berlin Buch /ID# 206859</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kinder- &amp; Jugendrheumatologie /ID# 206571</name>
      <address>
        <city>Hamburg</city>
        <zip>22081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik St. Augustin /ID# 203264</name>
      <address>
        <city>Sankt Augustin</city>
        <zip>53757</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem II. Számú Gyermekgyógyászati Klinika /ID# 208970</name>
      <address>
        <city>Budapest VIII</city>
        <state>Pest</state>
        <zip>1082</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>IRCCS Ospedale Pediatrico Bambino Gesù /ID# 203835</name>
      <address>
        <city>Rome</city>
        <state>Lazio</state>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Meyer /ID# 215576</name>
      <address>
        <city>Florence</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto G. Gaslini /ID# 203648</name>
      <address>
        <city>Genoa</city>
        <zip>16147</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro de Reumatologia Pediatrico de Puerto Rico /Id# 204406</name>
      <address>
        <city>Bayamon</city>
        <zip>00959</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>GCM Medical Group PSC - Hato Rey /ID# 211702</name>
      <address>
        <city>San Juan</city>
        <zip>00917-3104</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mindful Medical Research /ID# 204488</name>
      <address>
        <city>San Juan</city>
        <zip>00918-3756</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan de Deu /ID# 203915</name>
      <address>
        <city>Esplugues de Llobregat</city>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Infantil Universitario Nino Jesus /ID# 206466</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Univ Ramon y Cajal /ID# 203917</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz /ID# 203927</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Fe /ID# 203914</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Puerto Rico</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>October 27, 2018</study_first_submitted>
  <study_first_submitted_qc>October 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2018</study_first_posted>
  <last_update_submitted>April 6, 2020</last_update_submitted>
  <last_update_submitted_qc>April 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Upadacitinib</keyword>
  <keyword>ABT-494</keyword>
  <keyword>Polyarticular Course Juvenile Idiopathic Arthritis (pcJIA)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Juvenile</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Upadacitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

